Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor. We show 44 historical shares outstanding datapoints in our CYTK shares outstanding history coverage, used to compute CYTK market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CYTK market cap history over the course of time is important for investors
interested in comparing CYTK's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CYTK versus a peer is one thing; comparing
CYTK market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CYTK can fluctuate over the course of history.
With this page we aim to empower investors researching CYTK by allowing them to research the CYTK market cap history. |
Free CYTK Email Alerts:
Video: The Importance of Market Cap
